More later -- Here is the full story link. And here's the snippet I found most intriguing:
. . . .there are several opportunities for Bayer, but tight capital markets may make a total takeover difficult. He said Bayer is more likely to acquire a product line or specialty area such as vaccines.
That's what makes Schering-Plough's vaccine company Intervet particularly attractive, say UniCredit analyst Andreas Heine and Sal. Oppenheim analyst Christian Faitz. However, they say Intervet's price tag, which the Wall Street Journal estimates at between $6 billion and $8 billion, would mean Bayer would have to make a capital hike to pay for it. . . .
No comments:
Post a Comment